Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: A single center study
Vishal Bhatnagar(Yashoda Hospital), Ashraf Badros(University of Maryland, Baltimore), Todd Milliron(University of Maryland, Baltimore), Carolynn Harris(University of Maryland, Baltimore), Yin Wu(Yangzhou University), Maria R. Baer(University of Maryland, Baltimore), Saul Yanovich(Virginia Commonwealth University Medical Center), Aaron P. Rapoport(University of Maryland, Baltimore), Kathleen Ruehle(University of Maryland, Baltimore), Edward A. Sausville(University of Maryland, Baltimore), Olga Goloubeva(University of Maryland, Baltimore)
Cited by 55
Related Papers
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever
|New England Journal of Medicine|2002|986
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782